Rigel Pharmaceuticals (RIGL) EBT (2010 - 2026)

Rigel Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• In Q1 2026, EBT rose 1.27% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $122.0 million (up 219.94% YoY), while the FY2025 annual figure was $121.8 million, up 563.33% from the prior year.
• EBT for Q1 2026 stood at $11.7 million, down from $22.7 million in the prior quarter.
• The five-year high for EBT was $60.0 million in Q2 2025, with the low at -$27.4 million in Q1 2022.
• The 5-year median for EBT is -$61000.0 (2023), against an average of $3.9 million.
• The sharpest annual moves came in 2022 and 2024: EBT tumbled 166.5% in 2022, then jumped 25054.1% in 2024.
• Rigel Pharmaceuticals' EBT stood at $1.4 million in 2022, then slumped by 104.35% to -$61000.0 in 2023, then surged by 25054.1% to $15.2 million in 2024, then surged by 49.22% to $22.7 million in 2025, then plunged by 48.68% to $11.7 million in 2026.
• Business Quant data shows RIGL's EBT at $11.7 million in Q1 2026, $22.7 million in Q4 2025, and $27.6 million in Q3 2025.